Related Experiment Video
Updated: Aug 4, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Evaluation of radiolabeled type IV collagen fragments as potential tumor imaging agents
W B Edwards1, C J Anderson, G B Fields
1Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Abstract:
The objective of this study was to examine radiopharmaceuticals that target the alpha3beta1 integrin to determine if these agents target tumors for diagnostic imaging and/or targeted radiotherapy of cancer. Prior studies had shown that residues 531-542 from the alpha1 chain of type IV collagen bind a variety of tumor cell alpha3beta1 integrins. A peptide mimic of this sequence containing all D-amino acids (designated D-Hep-III) was synthesized by solid-phase methods. The tetraazamacrocyclic chelator, TETA, was conjugated to the peptide while it was resin-bound. TETA-D-Hep-III and D-Hep-III were radiolabeled with 64Cu and 125I, respectively, in high specific activity and radiochemical purity. Heterologous competitive binding assays between D-Hep-III and either 125I-D-Hep-III or 64Cu-TETA-D-Hep-III indicated low micromolar affinity of D-Hep-III. The biodistribution of each radiolabeled analogue of D-Hep-III was carried out in rats and tumor-bearing mice. Both analogues were rapidly cleared from the blood in normal rats, with the kidneys receiving the highest accumulation of each. SKOV3 human ovarian tumor cells, known to strongly express alpha3beta1, were xenografted in SCID mice. Localization of 125I-D-Hep III and 64Cu-TETA-D-Hep III in the xenografts were low (<2% ID/g), and in the case of 125I-D-Hep III, not inhibited by a competitive dose of D-Hep III. The low tumor accumulation is likely not due to receptor down-regulation, but rather due to the weak affinity of the radioligands for the alpha3beta1 integrin.
Insights
Researchers investigated radiopharmaceuticals targeting alpha3beta1 integrins for cancer imaging and therapy. The developed peptide analogues showed weak affinity, resulting in low tumor accumulation, limiting their potential for targeted cancer applications.
Area of Science:
- Oncology
- Radiopharmaceutical Chemistry
- Molecular Imaging
Background:
- Integrins, such as alpha3beta1, are implicated in tumor progression and metastasis.
- Targeting specific integrins with radiopharmaceuticals offers potential for cancer diagnosis and therapy.
Purpose of the Study:
- To evaluate radiolabeled peptide analogues targeting the alpha3beta1 integrin for their potential in cancer imaging and radiotherapy.
- To synthesize and characterize a D-amino acid peptide mimic (D-Hep-III) of a collagen IV sequence that binds alpha3beta1 integrins.
Main Methods:
- Solid-phase peptide synthesis of D-Hep-III and conjugation with TETA chelator.
- Radiolabeling of D-Hep-III with 125I and 64Cu-TETA-D-Hep-III with 64Cu.
- In vitro competitive binding assays to determine ligand affinity.
- In vivo biodistribution studies in rats and tumor-bearing mice xenografted with alpha3beta1-expressing SKOV3 cells.
Main Results:
- D-Hep-III demonstrated low micromolar affinity for alpha3beta1 integrins.
- Both radiolabeled analogues (125I-D-Hep-III and 64Cu-TETA-D-Hep-III) were rapidly cleared from circulation in normal rats, with high kidney accumulation.
- Low tumor uptake (<2% ID/g) was observed in SKOV3 xenografts, and this uptake was not inhibited by a competitive dose of D-Hep-III.
Conclusions:
- The developed radioligands exhibit weak affinity for the alpha3beta1 integrin, leading to insufficient tumor accumulation for effective diagnostic imaging or targeted radiotherapy.
- Further optimization of radioligand design is necessary to enhance affinity and tumor targeting for potential clinical applications.
More Related Videos
07:03Imaging Denatured Collagen Strands In vivo and Ex vivo via Photo-triggered Hybridization of Caged Collagen Mimetic Peptides
Published on: January 31, 2014
06:46Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
Published on: May 8, 2017
